Ryan W Stidham1, Amanda S Guentner2, Julie L Ruma3, Shail M Govani4, Akbar K Waljee4, Peter D R Higgins5. 1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan. Electronic address: ryanstid@med.umich.edu. 2. Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 3. Department of Radiology, Veterans Affairs Health System, Ann Arbor, Michigan. 4. Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan; VA Ann Arbor Health Services Research & Development Center for Clinical Management Research, Ann Arbor, Michigan. 5. Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan.
Abstract
BACKGROUND & AIMS: It is a challenge to predict how patients with small bowel Crohn's disease (CD) will respond to intensified medical therapy. We aimed to identify factors that predicted surgery within 2 years of hospitalization for CD, to guide medical versus surgical management decisions. METHODS: We performed a retrospective review of adults hospitalized for small bowel CD from 2004 through 2012 at a single academic referral center. Subjects underwent abdominal computed tomography or magnetic resonance imaging within 3 weeks of hospitalization. Imaging characteristics of small bowel dilation, bowel wall thickness, and disease activity were assessed by a single, blinded radiologist. Multivariate analysis by Cox proportional hazards regression techniques was used to generate a prediction model of intestinal resection within 2 years. RESULTS: A total of 221 subjects met selection criteria, with 32.6% undergoing surgery within 2 years of index admission. Bivariate analysis showed high-dose steroid use (>40 mg), ongoing treatment with anti-tumor necrosis factor agents at admission, platelet count, platelet:albumin ratio, small bowel dilation (≥35 mm), and bowel wall thickness to predict surgery (P ≤ .01). Multivariate modeling demonstrated small bowel dilation >35 mm (hazard ratio, 2.92; 95% confidence interval, 1.73-4.94) and a platelet:albumin ratio ≥125 (hazard ratio, 2.13; 95% confidence interval, 1.15-3.95) to predict surgery. Treatment with anti-tumor necrosis factor agents at admission conferred a nonsignificant increased trend for risk of surgery (hazard ratio, 1.61; 95% confidence interval, 0.994-2.65). CONCLUSIONS: Small bowel dilation >35 mm and high platelet:albumin ratios are independent and synergistic risk factors for future surgery in patients with structuring small bowel CD. Platelet:albumin ratios may capture the relationship between acute inflammation and cumulative damage and serve as markers of intestinal disease that cannot be salvaged with medical therapy.
BACKGROUND & AIMS: It is a challenge to predict how patients with small bowel Crohn's disease (CD) will respond to intensified medical therapy. We aimed to identify factors that predicted surgery within 2 years of hospitalization for CD, to guide medical versus surgical management decisions. METHODS: We performed a retrospective review of adults hospitalized for small bowel CD from 2004 through 2012 at a single academic referral center. Subjects underwent abdominal computed tomography or magnetic resonance imaging within 3 weeks of hospitalization. Imaging characteristics of small bowel dilation, bowel wall thickness, and disease activity were assessed by a single, blinded radiologist. Multivariate analysis by Cox proportional hazards regression techniques was used to generate a prediction model of intestinal resection within 2 years. RESULTS: A total of 221 subjects met selection criteria, with 32.6% undergoing surgery within 2 years of index admission. Bivariate analysis showed high-dose steroid use (>40 mg), ongoing treatment with anti-tumor necrosis factor agents at admission, platelet count, platelet:albumin ratio, small bowel dilation (≥35 mm), and bowel wall thickness to predict surgery (P ≤ .01). Multivariate modeling demonstrated small bowel dilation >35 mm (hazard ratio, 2.92; 95% confidence interval, 1.73-4.94) and a platelet:albumin ratio ≥125 (hazard ratio, 2.13; 95% confidence interval, 1.15-3.95) to predict surgery. Treatment with anti-tumor necrosis factor agents at admission conferred a nonsignificant increased trend for risk of surgery (hazard ratio, 1.61; 95% confidence interval, 0.994-2.65). CONCLUSIONS:Small bowel dilation >35 mm and high platelet:albumin ratios are independent and synergistic risk factors for future surgery in patients with structuring small bowel CD. Platelet:albumin ratios may capture the relationship between acute inflammation and cumulative damage and serve as markers of intestinal disease that cannot be salvaged with medical therapy.
Authors: David T Rubin; Parvez Mulani; Jingdong Chao; Paul F Pollack; Arielle G Bensimon; Andrew P Yu; Subrata Ghosh Journal: Inflamm Bowel Dis Date: 2011-09-01 Impact factor: 5.325
Authors: A Jauregui-Amezaga; J Rimola; I Ordás; S Rodríguez; A Ramírez-Morros; M Gallego; M C Masamunt; J Llach; B González-Suárez; E Ricart; J Panés Journal: Gut Date: 2014-12-16 Impact factor: 23.059
Authors: Jason K Hou; Mimi Tan; Ryan W Stidham; John Colozzi; Devon Adams; Hashem El-Serag; Akbar K Waljee Journal: Dig Dis Sci Date: 2014-05-10 Impact factor: 3.199
Authors: Laurent Peyrin-Biroulet; Edward V Loftus; Jean-Frederic Colombel; William J Sandborn Journal: Am J Gastroenterol Date: 2009-10-27 Impact factor: 10.864
Authors: L Menchén; I Marín-Jiménez; E G Arias-Salgado; T Fontela; P Hernández-Sampelayo; M C García Rodríguez; N V Butta Journal: Gut Date: 2008-11-27 Impact factor: 23.059
Authors: A Fabre; J Marchal-Sommé; S Marchand-Adam; C Quesnel; R Borie; M Dehoux; C Ruffié; J Callebert; J-M Launay; D Hénin; P Soler; B Crestani Journal: Eur Respir J Date: 2008-03-05 Impact factor: 16.671
Authors: Corey A Siegel; Sadie M Marden; Sarah M Persing; Robin J Larson; Bruce E Sands Journal: Clin Gastroenterol Hepatol Date: 2009-01-24 Impact factor: 11.382
Authors: Alain M Schoepfer; Mohamed-Ali Dehlavi; Nicolas Fournier; Ekaterina Safroneeva; Alex Straumann; Valérie Pittet; Laurent Peyrin-Biroulet; Pierre Michetti; Gerhard Rogler; Stephan R Vavricka Journal: Am J Gastroenterol Date: 2013-08-27 Impact factor: 10.864
Authors: Bethany A Reutemann; Joshua A Turkeltaub; Mahmoud Al-Hawary; Akbar K Waljee; Peter D R Higgins; Ryan W Stidham Journal: Inflamm Bowel Dis Date: 2017-10 Impact factor: 5.325
Authors: Ryan W Stidham; Yumu Liu; Binu Enchakalody; Tony Van; Venkataramu Krishnamurthy; Grace L Su; Ji Zhu; Akbar K Waljee Journal: Inflamm Bowel Dis Date: 2021-07-27 Impact factor: 5.325